MarkLogic Stock

marklogic.comEnterprise SoftwareFounded: 1900Funding to Date: $187.49MM

MarkLogic is the developer of an operational and transactional Enterprise NoSQL database platform designed to empower customers to build next generation applications on a unified, 360-degree view of their data.

Register for Details

For more details on financing and valuation for MarkLogic, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for MarkLogic.

Register Today

MarkLogic investors also invested in these private companies

Team

Management Team

Gary Bloom
Chief Executive Officer and President
David Ponzini
Executive Vice President, Corporate Development
Robert Im
Vice President and General Counsel
Christopher Lindblad
Founder
Adrian Carr
Executive Vice President and Chief Operation Officer
Matt Allen
Vice President, Corporate Marketing
David Gorbet
Senior Vice President, Engineering
Peter S Norman
Executive Vice President and Chief Financial Officer
Joe Pasqua
Executive Vice President, Products
Linda Kato
Vice President of People

Board Members

Christopher Lindblad
Gary Bloom
Greg Santora
Tom Banahan
Tenaya Capital
Pat Grady
Sequoia Capital

Other companies like MarkLogic in the Enterprise Software sector

Sector
Last Round Est. Valuation
$7.3B
Sector
Last Round Est. Valuation
$37.89B
Sector
Last Round Est. Valuation
$7.53B
Sector
Last Round Est. Valuation
$12.38B
Sector
Last Round Est. Valuation
$11.25B
Sector
Last Round Est. Valuation
$8.93B
Sector
Last Round Est. Valuation
$4.14B

News

MarkLogic claims that the Data Hub Service provides a fast and cost-effective way for enterprises to integrate, store, analyze and secure mission-critical data in the cloud. None of this is ever easy, despite what company marketers will tell you.
The Document Databases market report correspondingly comprises a detailed market & vendor landscape aside from a SWOT analysis of the major players. Hence, the data provided is comprehensive, reliable, and the outcome of extensive research.
Biotech companies will open new doors to personalized drug development.